Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis

Schizophrenia Research

Volumn 174, Issue 1-3, 2016, Pages 156-160

  González Blanco, Leticia ^a,d   Greenhalgh, Anne Marie D ^b   Garcia Rizo, Clemente ^c,d,e   Fernandez Egea, Emilio ^f,g   Miller, Brian J ^h   Kirkpatrick, Brian ^b  

^a UNIVERSITY OF OVIEDO   (Spain)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Meta analysis; Prolactin; Psychosis; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN;

AGE DISTRIBUTION; BODY MASS; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SEX RATIO; SMOKING; SYSTEMATIC REVIEW (TOPIC); BLOOD; FEMALE; MALE; META ANALYSIS; PSYCHOSIS;

FEMALE; HUMANS; MALE; PROLACTIN; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84962383366     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.03.018     Document Type: Review

References (45)

1. Abel K.M., O'Keane V., Murray R.M. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Br. J. Psychiatry 1996, 168(1):57-60.
2. Abel K.M., O'Keane V., Murray R.M., Cleare A.J. Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression. Psychoneuroendocrinology 1997, 22(7):539-548.
3. Albayrak Y., Beyazyüz M., Beyazyüz E., Kuloğlu M. Increased serum prolactin levels in drug-naive first-episode male patients with schizophrenia. Nord. J. Psychiatry. 2014, 68(5):341-346.
4. Aston J., Rechsteiner E., Bull N., Borgwardt S., Gschwandtner U., Riecher-Rossler A. Hyperprolactinaemia in early psychosis-not only due to antipsychotics. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34(7):1342-1344.
5. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum. Psychopharmacol. 2008, 23(3):201-209.
6. Balbach L., Wallaschofski H., Völzke H., Nauck M., Dörr M., Haring R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?. BMC Endocr. Disord. 2013, 13(12).
7. Bicikova M., Hampl R., Hill M., Ripova D., Mohr P., Putz Z. Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuro Endocrinol. Lett. 2011, 32(2):141-147.
8. Bloemen O.J., de Koning M.B., Gleich T., Meijer J., de Haan L., Linszen D.H., Booij J., van Amelsvoort T.A. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at ultra high risk for psychosis. Eur. Neuropsychopharmacol. 2013, 23(2):126-132.
9. Byerly M., Suppes T., Tran Q.V., Baker R.A. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J. Clin. Psychopharmacol. 2007, 27(6):639-661.
10. Chatterjee S.B. Dopamine related hormone levels in acute schizophrenia: (a study of 84 patients). Indian J. Psychiatry 1998, 30(1):7-11.
11. Cochran W.B. The comparison of percentages in matched samples. Biometrika 1950, 37(3-4):256-266.
12. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7(3):177-188.
13. Engler H., Doenlen R., Riether C., Engler A., Niemi M.B., Besedovsky H.O., del Rey A., Pacheco-López G., Feldon J., Schedlowski M. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease. Brain Behav. Immun. 2009, 23(4):518-526.
14. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194(5):434-438.
15. Fernandez-Egea E., Bruna A., Garcia-Rizo C., Bernardo M., Kirkpatrick B. Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis. Mol. Psychiatry 2009, 14(11):989-991.
16. Fernandez-Egea E., García-Rizo C., Miller B., Parellada E., Justicia A., Bernardo M., Kirkpatrick B. Testosterone in newly diagnosed, antipsychotic-naive men with nonaffective psychosis: a test of the accelerated aging hypothesis. Psychosom. Med. 2011, 73(8):643-647.
17. Friedrich N., Schneider H.J., Spielhagen C., Markus M.R., Haring R., Grabe H.J., Buchfelder M., Wallaschofski H., Nauck M. The association of serum prolactin concentration with inflammatory biomarkers - cross-sectional findings from the population-based Study of Health in Pomerania. Clin. Endocrinol. 2011, 75(4):561-566.
18. Garcia-Rizo C., Fernandez-Egea E., Oliveira C., Justicia A., Parellada E., Bernardo M., Kirkpatrick B. Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophr. Res. 2012, 134(1):16-19.
19. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64(20):2291-2314.
20. Haring R., Friedrich N., Völzke H., Vasan R.S., Felix S.B., Dörr M., Meyer zu Schwabedissen H.E., Nauck M., Wallaschofski H. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur. Heart J. 2014, 35(18):1215-1221.
21. Hert M.De, Peuskens J., Sabbe T., Mitchell A.J., Stubbs B., Neven P., et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr. Scand. 2016, 133:5-22.
22. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. 9.7. Sensitivity Analyses. The Cochrane Collaboration 2011, (updated March 2011).
23. Howes O.D., Wheeler M.J., Meaney A.M., O'Keane V., Fogelman I., Blake G., Murray R.M., Smith S. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J. Clin. Psychopharmacol. 2005, 25(3):259-261.
24. Jaroenporn S., Nagaoka K., Kasahara C., Ohta R., Watanabe G., Taya K. Physiological roles of prolactin in the adrenocortical response to acute restraint stress. Endocr. J. 2007, 54(4):703-711.
25. Kleinman J.E., Weinberger D.R., Rogol A.D. Plasma prolactin concentrations and psychopathology in chronic schizophrenia. Arch. Gen. Psychiatry 1982, 39(6):655-657.
26. Kuruvilla K., Kuruvilla A., Kanagasabapathy A.S. Serum prolactin levels in schizophrenia: effects of neuroleptic medication - a preliminary study. Indian J. Psychiatry 1986, 28(3):237-241.
27. Lee B.H., Kim Y.K. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2006, 30(4):658-662.
28. Messini C.I., Dafopoulos K., Chalvatzas N., Georgoulias P., Anifandis G., Messinis I.E. Effect of ghrelin and thyrotropin-releasing hormone on prolactin secretion in normal women. Horm. Metab. Res. 2010, 42(3):204-208.
29. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
30. Misra M., Papakostas G.I., Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin. Psychiatry 2004, 65(12):607-618.
31. Moher D., Liberati A., Tetzlaff J., Altman D.G., The PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 2009, 62(10):1006-1012.
32. Montalvo I., Gutiérrez-Zotes A., Creus M., Monseny R., Ortega L., Franch J., Lawrie S.M., Reynolds R.M., Vilella E., Labad J. Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. PLoS One 2014, 9(2):e89428.
33. Monteleone P., Tortorella A., Borriello R., Cassandro P., Maj M. Prolactinhyperresponsiveness to d-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study. Biol. Psychiatry 1999, 45(12):1606-1611.
34. Ohta C., Yasui-Furukori N., Furukori H., Tsuchimine S., Saito M., Nakagami T., Yoshizawa K., Kaneko S. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35(2):573-576.
35. Oride A., Kanasaki H., Purwana I.N., Miyazaki K. Possible involvement of mitogen-activated protein kinase phosphatase-1 (MKP-1) in thyrotropin-releasing hormone (TRH)-induced prolactin gene expression. Biochem. Biophys. Res. Commun. 2009, 382(4):663-667.
36. Rajkumar R.P. Prolactin and psychopathology in schizophrenia: a literature review and reappraisal. Schizophr. Res. Treatment 2014, 2014:12.
37. Ranabir S., Reetu K. Stress and hormones. Indian J. Endocrinol. Metab. 2011, 15(1):18-22.
38. Rao M.L., Gross G., Strebel B., Bräunig P., Huber G., Klosterkötter J. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Res. 1990, 34(3):243-257.
39. Riecher-Rössler A., Rybakowski J.K., Pflueger M.O., Beyrau R., Kahn R.S., Malik P., Fleischhacker W.W., EUFEST Study Group Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol. Med. 2013, 43(12):2571-2582.
40. Segal M., Avital A., Berstein S., Derevenski A., Sandbank S., Weizman A. Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31(2):378-382.
41. Sharma R.P., Singh V., Janicak P.G., Javaid J.I., Pandey G.N. The prolactin response to fenfluramine in schizophrenia is associated with negative symptoms. Schizophr. Res. 1999, 39(1):85-89.
42. Song X., Fan X., Zhang J., Zheng H., Li X., Pang L., Chen X., Zhang W., Harrington A., Ziedonis D., Lv L. Prolactin serum levels correlate with inflammatory status in drug-naïve first-episode schizophrenia. World J. Biol. Psychiatry. 2014, 15(7):546-552.
43. Szarfman A., Tonning J.M., Levine J.G., Doraiswamy P.M. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006, 26(6):748-758.
44. Walter A., Studerus E., Smieskova R., Tamagni C., Rapp C., Borgwardt S.J., Riecher-Rössler A. Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis. CNS Spectr. 2015, 20(2):122-129.
45. Xu T., Chan R.C., Compton M.T. Minor physical anomalies in patients with schizophrenia, unaffected first-degree relatives, and healthy controls: a meta-analysis. PLoS One 2011, 6(9):e24129.